Dossiers, industry reports and further studies.
→ All Dossiers
→ All Industry Reports
→ All Toplists
→ All Outlook Reports
→ Study Database We create infographics, animated charts, microsites and publications in your desired corporate design. Add a new visual dimension to your communication & marketing activities. Read more → Infographics Bulletin
| Number of drugs no longer under development | |
|---|---|
| 1998 | 2 |
| 1999 | 4 |
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 8 |
| 2003 | 4 |
| 2004 | 11 |
| 2005 | 7 |
| 2006 | 6 |
| 2007 | 25 |
| 2008 | 15 |
| 2009 | 11 |
| 2010 | 14 |
| 2011 | 13 |
| 2012 | 11 |
| 2013 | 23 |
| 2014 | 6 |
Show further information
Complete Source Details
This statistic depicts the number of unsuccessful lung cancer drugs that were developed in the United States from 1998 to 2014. In 2011, there were 13 unsuccessfully developed lung cancer drugs. Since 1998, there have been 167 total medicines being developed for lung cancer that were discontinued, suspended, or had no development reported and 10 approved medications.
+
+Currently, Statista provides more than 1 million statistics. 93 percent (all Premium content) are exclusively accessible via our professional accounts.
As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.
$588*
per year
* All products require an annual contract.
Prices do not include sales tax
(New York residents only).
Register in seconds and access exclusive features.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Exclusive Statista studies on market-relevant topics: 
